- Home
- RACC vs PMN Comparison
RACC vs PMN Comparison
Compare RACC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RACC | PMN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.8M | 115.5M |
| IPO Year | 2026 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RACC | PMN |
|---|---|---|
| Price | $11.00 | $13.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 3.7K | ★ 42.1K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.39 | $0.29 |
| 52 Week High | $12.38 | $27.40 |
Technical Indicators
Market Signals| Indicator | RACC | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 73.74 |
| Support Level | $10.40 | $10.55 |
| Resistance Level | $12.38 | $19.85 |
| Average True Range (ATR) | 0.59 | 0.90 |
| MACD | 0.04 | 0.34 |
| Stochastic Oscillator | 30.65 | 81.44 |
Price Performance
Historical ComparisonAbout RACC Research Alliance Corporation III Class A Ordinary Shares
Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.